Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 347 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 8 Gy Clear all
Recruiting Not applicable Interventional

Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)

NCT07142967
View directory record Official record
Conditions
Intraprostatic Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT), Androgen Deprivation Therapy (ADT)
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 31, 2026, 2:04 PM EDT
Completed No phase listed Observational

Cardiotoxicity of Radiation Therapy (CTRT)

NCT02769299
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Mediastinal Lymphomas
Interventions
Radiation Therapy
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

Chemoimmunotherapy and Radiation in Pancreatic Cancer

NCT01903083
View directory record Official record
Conditions
Locally Advanced Malignant Neoplasm
Interventions
Tadalafil, Gemcitabine, Radiation, Pancreaticoduodenectomy
Drug · Radiation · Procedure
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Not applicable Interventional Results available

Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer

NCT00694577
View directory record Official record
Conditions
Ductal Breast Cancer
Interventions
Partial Breast Irradiation using 32 Gy / 8 fractions, Partial Breast Irradiation using 36 Gy / 9 fractions, Partial Breast Irradiation using 40 Gy /10 fractions
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Not applicable Interventional

Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL

NCT03042585
View directory record Official record
Conditions
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Interventions
Total body irradiation
Radiation
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 31, 2026, 2:04 PM EDT
Withdrawn Phase 2 Interventional

SBRT as a Vaccination for Metastatic Melanoma

NCT04042506
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Nivolumab 10 MG/ML Intravenous Solution [OPDIVO], Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 31, 2026, 2:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma

NCT04225039
View directory record Official record
Conditions
Glioblastoma
Interventions
INCMGA00012, INCAGN01876, SRS, Brain surgery
Drug · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 31, 2026, 2:04 PM EDT
Active, not recruiting Not applicable Interventional

Stereotactic Ablative Radiation Therapy for Prostate Cancer

NCT05668351
View directory record Official record
Conditions
Prostate Cancer
Interventions
SUPR-SABR treatment
Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 31, 2026, 2:04 PM EDT
Withdrawn Phase 1 Interventional

RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy

NCT02880345
View directory record Official record
Conditions
Urothelial Cancer
Interventions
PEMBROLIZUMAB, hypofractionated radiation
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

NCT01467115
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel
Radiation · Drug · Biological
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Not applicable Interventional Results available

Fractionated Stereotactic Radiosurgery for Large Brain Metastases

NCT02054689
View directory record Official record
Conditions
Large Brain Mets
Interventions
Fractionated Stereotactic Radiosurgery
Radiation
Lead sponsor
Steven Burton
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 31, 2026, 2:04 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

NCT04957290
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Interventions
NOX66, EBRT
Drug · Radiation
Lead sponsor
Noxopharm Limited
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Beverly Hills, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 31, 2026, 2:04 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

NCT01222572
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer, NSCLC
Interventions
Stereotactic boost, Conventional RT, Etoposide, Cisplatin
Radiation · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 31, 2026, 2:04 PM EDT
Terminated Phase 1Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00004093
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, Gemcitabine, paclitaxel, vinorelbine, radiation therapy, Navelbine, Taxol
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 31, 2026, 2:04 PM EDT
Active, not recruiting Not applicable Interventional

FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax

NCT05524064
View directory record Official record
Conditions
Bone Metastases in the Thorax
Interventions
FLASH Radiotherapy
Radiation
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Peoria, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 31, 2026, 2:04 PM EDT
Active, not recruiting Not applicable Interventional

Randomized MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy

NCT02307058
View directory record Official record
Conditions
Prostate Cancer
Interventions
LEAD RT, HEIGHT RT
Radiation
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 85 Years · Male only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

NCT03767582
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Interventions
Stereotactic Body Radiation (SBRT), Nivolumab, CCR2/CCR5 dual antagonist, GVAX
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 31, 2026, 2:04 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

NCT03245541
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Durvalumab, Stereotactic Ablative Body Radiotherapy (SABR)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 31, 2026, 2:04 PM EDT
Withdrawn Phase 2 Interventional

Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer

NCT00226746
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal
Interventions
Paclitaxel and gemcitabine
Drug
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2020 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

NCT03107182
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma, HNSCC
Interventions
nab-paclitaxel, Carboplatin, Nivolumab, Cisplatin, Hydroxyurea, 5-FU, Dexamethasone, Famotidine, Diphenhydramine, Paclitaxel, Transoral robotic surgery (TORS), Adjuvant RT, Chemoradiotherapy
Drug · Procedure · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 31, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Results available

Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.

NCT01041508
View directory record Official record
Conditions
Leukemia Lymphoblastic, Acute, Acute Myeloid Leukemia, Neoplasm Recurrent
Interventions
Clofarabine, Total Body Irradiation, Stem Cell Transplantation, Cyclosporine, Mycophenolate Mofetil
Drug · Radiation · Other
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Columbus, Ohio • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 31, 2026, 2:04 PM EDT
Recruiting Phase 1 Interventional

Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer

NCT07700420
View directory record Official record
Conditions
Gastro-esophageal Junction (GEJ) Cancer, Esophagus Cancer
Interventions
PULSAR- Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)(D)
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 31, 2026, 2:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

NCT03809000
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog
Radiation · Drug
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
106
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 31, 2026, 2:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma

NCT00846742
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Stanford V Chemotherapy, Radiation Therapy
Drug · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
6
States / cities
Palo Alto, California • San Diego, California • Peoria, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 31, 2026, 2:04 PM EDT